nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—HTR5A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0453	0.0453	CbGpPWpGaD
Asenapine—HTR5A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.036	0.036	CbGpPWpGaD
Asenapine—HTR5A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0274	0.0274	CbGpPWpGaD
Asenapine—HTR1E—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0245	0.0245	CbGpPWpGaD
Asenapine—HTR1E—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0195	0.0195	CbGpPWpGaD
Asenapine—HRH2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0173	0.0173	CbGpPWpGaD
Asenapine—HTR1D—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0166	0.0166	CbGpPWpGaD
Asenapine—HTR1B—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0162	0.0162	CbGpPWpGaD
Asenapine—DRD4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.016	0.016	CbGpPWpGaD
Asenapine—HTR5A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0155	0.0155	CbGpPWpGaD
Asenapine—HTR1E—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0148	0.0148	CbGpPWpGaD
Asenapine—DRD3—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0142	0.0142	CbGpPWpGaD
Asenapine—HTR5A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0141	0.0141	CbGpPWpGaD
Asenapine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0133	0.0133	CbGpPWpGaD
Asenapine—HTR7—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0133	0.0133	CbGpPWpGaD
Asenapine—HRH2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0132	0.0132	CbGpPWpGaD
Asenapine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0132	0.0132	CbGpPWpGaD
Asenapine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0129	0.0129	CbGpPWpGaD
Asenapine—ADRA2B—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0128	0.0128	CbGpPWpGaD
Asenapine—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0127	0.0127	CbGpPWpGaD
Asenapine—HTR1A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0124	0.0124	CbGpPWpGaD
Asenapine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0121	0.0121	CbGpPWpGaD
Asenapine—ADRA2C—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.012	0.012	CbGpPWpGaD
Asenapine—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0114	0.0114	CbGpPWpGaD
Asenapine—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0113	0.0113	CbGpPWpGaD
Asenapine—DRD2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0109	0.0109	CbGpPWpGaD
Asenapine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0103	0.0103	CbGpPWpGaD
Asenapine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0102	0.0102	CbGpPWpGaD
Asenapine—HTR6—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Asenapine—HTR7—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Asenapine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Asenapine—HTR1D—GPCR ligand binding—CXCL11—nasal cavity cancer	0.01	0.01	CbGpPWpGaD
Asenapine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00984	0.00984	CbGpPWpGaD
Asenapine—HTR1B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00984	0.00984	CbGpPWpGaD
Asenapine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00979	0.00979	CbGpPWpGaD
Asenapine—ADRA2A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.00973	0.00973	CbGpPWpGaD
Asenapine—DRD4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00968	0.00968	CbGpPWpGaD
Asenapine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00952	0.00952	CbGpPWpGaD
Asenapine—HTR2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00924	0.00924	CbGpPWpGaD
Asenapine—DRD1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00871	0.00871	CbGpPWpGaD
Asenapine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00864	0.00864	CbGpPWpGaD
Asenapine—DRD3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0086	0.0086	CbGpPWpGaD
Asenapine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0085	0.0085	CbGpPWpGaD
Asenapine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00848	0.00848	CbGpPWpGaD
Asenapine—HTR1E—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00837	0.00837	CbGpPWpGaD
Asenapine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00832	0.00832	CbGpPWpGaD
Asenapine—HTR5A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00832	0.00832	CbGpPWpGaD
Asenapine—ADRB1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00783	0.00783	CbGpPWpGaD
Asenapine—ADRA2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00776	0.00776	CbGpPWpGaD
Asenapine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00773	0.00773	CbGpPWpGaD
Asenapine—ADRB2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00766	0.00766	CbGpPWpGaD
Asenapine—HTR1E—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0076	0.0076	CbGpPWpGaD
Asenapine—HTR1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00749	0.00749	CbGpPWpGaD
Asenapine—HRH2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00746	0.00746	CbGpPWpGaD
Asenapine—HTR2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00745	0.00745	CbGpPWpGaD
Asenapine—ADRA2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00725	0.00725	CbGpPWpGaD
Asenapine—HRH2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00677	0.00677	CbGpPWpGaD
Asenapine—DRD2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00658	0.00658	CbGpPWpGaD
Asenapine—HTR2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00647	0.00647	CbGpPWpGaD
Asenapine—HRH1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00646	0.00646	CbGpPWpGaD
Asenapine—ADRA1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00634	0.00634	CbGpPWpGaD
Asenapine—ADRA2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00589	0.00589	CbGpPWpGaD
Asenapine—HTR6—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00572	0.00572	CbGpPWpGaD
Asenapine—HTR7—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00571	0.00571	CbGpPWpGaD
Asenapine—HTR1D—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00568	0.00568	CbGpPWpGaD
Asenapine—HTR1B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00556	0.00556	CbGpPWpGaD
Asenapine—DRD4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00547	0.00547	CbGpPWpGaD
Asenapine—HTR2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00522	0.00522	CbGpPWpGaD
Asenapine—HTR6—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00519	0.00519	CbGpPWpGaD
Asenapine—HTR7—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00519	0.00519	CbGpPWpGaD
Asenapine—HTR1D—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00515	0.00515	CbGpPWpGaD
Asenapine—HTR1B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00505	0.00505	CbGpPWpGaD
Asenapine—DRD4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00497	0.00497	CbGpPWpGaD
Asenapine—DRD1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00492	0.00492	CbGpPWpGaD
Asenapine—HTR5A—Signaling Pathways—FRS2—nasal cavity cancer	0.0049	0.0049	CbGpPWpGaD
Asenapine—DRD3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00486	0.00486	CbGpPWpGaD
Asenapine—HTR2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00474	0.00474	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—CXCL11—nasal cavity cancer	0.00449	0.00449	CbGpPWpGaD
Asenapine—DRD1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00447	0.00447	CbGpPWpGaD
Asenapine—ADRB1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00443	0.00443	CbGpPWpGaD
Asenapine—DRD3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00441	0.00441	CbGpPWpGaD
Asenapine—ADRA2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00439	0.00439	CbGpPWpGaD
Asenapine—ADRB2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00433	0.00433	CbGpPWpGaD
Asenapine—HTR1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00423	0.00423	CbGpPWpGaD
Asenapine—HTR2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00421	0.00421	CbGpPWpGaD
Asenapine—ADRA2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0041	0.0041	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00402	0.00402	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—CXCL11—nasal cavity cancer	0.004	0.004	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00398	0.00398	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00393	0.00393	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00384	0.00384	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00383	0.00383	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00372	0.00372	CbGpPWpGaD
Asenapine—DRD2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00372	0.00372	CbGpPWpGaD
Asenapine—HTR2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00366	0.00366	CbGpPWpGaD
Asenapine—HRH1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00365	0.00365	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00358	0.00358	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00338	0.00338	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00333	0.00333	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00332	0.00332	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00331	0.00331	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00325	0.00325	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—CXCL11—nasal cavity cancer	0.00307	0.00307	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—CXCL11—nasal cavity cancer	0.00307	0.00307	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—CXCL11—nasal cavity cancer	0.00305	0.00305	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00302	0.00302	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00298	0.00298	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00293	0.00293	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.0028	0.0028	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—FRS2—nasal cavity cancer	0.00265	0.00265	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00264	0.00264	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00261	0.00261	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00237	0.00237	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—FRS2—nasal cavity cancer	0.00236	0.00236	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00235	0.00235	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00232	0.00232	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00227	0.00227	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00226	0.00226	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.0022	0.0022	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00199	0.00199	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00196	0.00196	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00196	0.00196	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00192	0.00192	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—FRS2—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—FRS2—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—FRS2—nasal cavity cancer	0.00179	0.00179	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00179	0.00179	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00176	0.00176	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—FRS2—nasal cavity cancer	0.00173	0.00173	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—FRS2—nasal cavity cancer	0.00165	0.00165	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—FRS2—nasal cavity cancer	0.00156	0.00156	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—FRS2—nasal cavity cancer	0.00154	0.00154	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—FRS2—nasal cavity cancer	0.0014	0.0014	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—FRS2—nasal cavity cancer	0.00139	0.00139	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—FRS2—nasal cavity cancer	0.00137	0.00137	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00134	0.00134	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00133	0.00133	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—FRS2—nasal cavity cancer	0.00118	0.00118	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00116	0.00116	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—FRS2—nasal cavity cancer	0.00115	0.00115	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00113	0.00113	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00105	0.00105	CbGpPWpGaD
